Hemorrhoidal disease (HD) is the most common proctological disease with a prevalence rate
that can reach approximately 4.4% of the population, with a particular peak in individuals
aged between 45 and 65 years. The most common presentation of HD is painless rectal bleeding
occurring during or immediately after defecation. Pain is rare in case of uncomplicated HD
and may be present in case of external hemorrhoidal thrombosis.
The decision-making to treat Hemorrhoidal thrombosis usually depends on the timing of the
onset of symptoms, with the surgical treatment favored if the onset of symptoms occurs within
72 hours.
Mesoglycan, a natural preparation of glycosaminoglycans (GAGs), is a polysaccharide complex
rich in sulfur radicals.
It is composed of heparan sulphate (47.5%), dermatan sulphate (35.5%), chondroitin sulfate
(8.5%) and slow heparin (8.5%).
Mesoglycan exerts antithrombotic activity (activation of antithrombin III and heparin
cofactor II) and profibrinolytic (stimulation of the activator tissue plasminogen) decreasing
plasma concentrations of fibrinogen without affecting the prothrombin time, the time of
partial thromboplastin or the remaining coagulation parameters. The rationale of this
double-blind randomized controlled clinical trial is to confirm/evaluate the efficacy and
safety of mesoglycan versus placebo in reducing the symptoms of hemorrhoidal disease and
their impact on quality of life.